CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Similar to the experiments using GO, we treated the CML and non-CML CD34+ cells using three different regimens in vitro, to mimic potential clinical scenarios when used in combination with IM: CsA or CsA + 2 μM IM 72 h treatment (CsA72); 72 h IM or NDC followed by 72 h CsA treatment (CsAIMCA); or, 72 h CsA followed by 72 h IM or NDC (CsACAIM).